Page last updated: 2024-08-26

peptide elongation factor 2 and deferoxamine

peptide elongation factor 2 has been researched along with deferoxamine in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Kasman, LM; Kelly, MM; Lu, P; McDermott, PJ; Spruill, L; Voelkel-Johnson, C; White, SJ	1

Other Studies

1 other study(ies) available for peptide elongation factor 2 and deferoxamine

Article	Year
Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free radical biology & medicine, 2007, Nov-01, Volume: 43, Issue:9 Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle; Cell Line, Tumor; Deferoxamine; Doxorubicin; Drug Synergism; Free Radicals; Humans; Hydrogen Peroxide; Iron Chelating Agents; Male; Peptide Elongation Factor 2; Phenotype; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Protein Synthesis Inhibitors; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein	2007

Article

Year

Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2.

Free radical biology & medicine, 2007, Nov-01, Volume: 43, Issue:9

Topics: Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Cycle; Cell Line, Tumor; Deferoxamine; Doxorubicin; Drug Synergism; Free Radicals; Humans; Hydrogen Peroxide; Iron Chelating Agents; Male; Peptide Elongation Factor 2; Phenotype; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Protein Synthesis Inhibitors; TNF-Related Apoptosis-Inducing Ligand; X-Linked Inhibitor of Apoptosis Protein

2007